Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development
Time: 10:15 am
day: Day One
Details:
- KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, reveal critical insights for targeted therapy development
- Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients
- Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes
